Waterstone Pharmaceuticals

Wuhan, China· Est. 2009

A China-based biotech developing polymer-based therapeutics for metabolic diseases like diabetic kidney disease, with a lead asset advancing to Phase 3 in the US.

waterstonepharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

A China-based biotech developing polymer-based therapeutics for metabolic diseases like diabetic kidney disease, with a lead asset advancing to Phase 3 in the US.

Metabolic DiseaseNephrology

Technology Platform

A proprietary high-molecular-weight/high-activity platform for the discovery, development, and manufacturing of polymer-based drug intermediates, active pharmaceutical ingredients (APIs), and advanced formulations.

Opportunities

The direct-to-Phase 3 pathway for WS016 in the large US DKD market presents a major value inflection point.

The polymer platform could be leveraged for other metabolic or chronic diseases requiring improved drug delivery.

Risk Factors

Clinical risk associated with Phase 3 trial of WS016; financial risk in funding a global Phase 3 study; competitive risk from established SGLT2 and non-steroidal MRA therapies in DKD.

Competitive Landscape

Competes with AstraZeneca (Farxiga) and Bayer (Kerendia) in DKD. Differentiation is based on a novel polymer-based mechanism of action, which may offer distinct efficacy or safety profiles compared to existing small molecules.

More companies in China →